#Tcel reverse merger fullAll statements, otheĪcer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos SyndromeĪcer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating OfficerĪcer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001Īcer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate UpdateĪcer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022Īcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International ConferenceĪcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual MeetingĪcer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome Discussions ongoing with FDA through special protocol assessment (SPA) seeking agreement on planned pivotal Phase 3 DiSCOVER triaĪcer Therapeutics Regains Compliance with Nasdaq Listing StandardĪcer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause Results anticipated in H2 2022Īcer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing FacilitiesĪcer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate UpdateĪcer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer Industry veteran with over 20 years of drug development experience to oversee advancement of Acer’s product pipelineĪcer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease Orphan designation provides potential for up to 10-year market exclusivity in the EU upon reĪcer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs Prescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023Īcer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs Acer has notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspectionįorward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. #Tcel reverse merger updateAll statements, otheĪcer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update Forward-looking Statements This presentation contains ?forward-looking statements? that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |